Relay Therapeutics, Inc. (RLAY)
14.24
+0.75
(+5.56%)
USD |
NASDAQ |
Jun 11, 16:00
14.24
0.00 (0.00%)
After-Hours: 18:46
Relay Therapeutics Gross Profit Margin (Quarterly) : 83.20% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 83.20% |
| December 31, 2025 | 91.44% |
| September 30, 2025 | |
| June 30, 2025 | -48.01% |
| March 31, 2025 | 84.27% |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | 86.06% |
| December 31, 2023 | |
| September 30, 2023 | 94.59% |
| Date | Value |
|---|---|
| June 30, 2023 | -1.02K% |
| March 31, 2023 | -429.6% |
| December 31, 2022 | -360.9% |
| September 30, 2022 | -200.3% |
| June 30, 2022 | -161.9% |
| March 31, 2022 | -132.7% |
| December 31, 2021 | -82.36% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 98.90% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Spyre Therapeutics, Inc. | -- |
| Catalyst Pharmaceuticals, Inc. | 83.82% |
| Exelixis, Inc. | 96.73% |
| Insmed, Inc. | 83.82% |
| United Therapeutics Corp. | 82.93% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -42.56% |
| Return on Assets | -38.75% |
| Return on Invested Capital | -40.31% |
| Profit Margin (Quarterly) | -2.44K% |
| Operating Margin (Quarterly) | -2.62K% |
| Return on Net Operating Assets | -425.5% |